

ChinaAMC Healthcare Fund

Fund Code
000945

Category
Aggressive Allocation
Fund

Morningstar Style Box


Morningstar 3 Year
Rating
Not Rating

Report Date 2016-07-31

Investment Objective

Centering around the development of China's big health industry, pursue the long-term appreciation in fund assets while reasonably controlling investment risks.

Portfolio Manager

CHEN Bin holds a Doctorate in Internal Medicine from Peking Union Medical College, Tsinghua University. In July 2009 he joined China AMC, where he acted as analyst of investment research department, etc.

Portfolio Manager's View

For the third quarter, further implementation of domestic supply-side reform and international risks may generate sustained pressure on risk appetite of investors. Influenced by "Quality Consistency Evaluation for Generic Drugs", the pharmaceuticals industry has entered the long period of "supply-side reform".

In the 3rd quarter, the Fund will, under the background that market risks occur frequently and "supply-side reform" undergoes, mainly select stocks which have sound cash flow and reasonable in valuation in the sub industry. The following points will be the focus of our allocation:

First, we'll invest heavily on the stocks of leading companies of traditional Chinese medicine decoction pieces. At present, the industry of traditional Chinese medicine decoction pieces is scattered, disordered and poorly behaved. The market share of Chinese medicine decoction pieces will constantly consolidate by the leading companies in the future as the new version of GMP is enforced, along with improvement on quality standards and the promotion by new technologies represented by "Intelligent TCM Pharmacy".

Second, we'll heavily invest in leading companies in prescription medicines. "Quality Consistency Evaluation for Generic Drugs" will become the keynote in the pharmaceutical industry in the next five years. A large number of inferior medium- and small-sized pharmaceutical factors will be forced to cede their market share. Meanwhile leading companies with certified quality and technologies will obtain a benefit from "supply-side reform".

Thirdly, we'll heavily invest in blood product companies. Blood product companies have very sound in cash flow, and this industry booms because of short market supply. Therefore, in the next three years, it's expected that industry leading companies will gradually grow into oligopoly companies in the blood product industry.

Fourthly, we'll heavily invest in companies of children's drugs. The whole society attaches great importance to the safety of children's drugs, which will bring more investment opportunities to this segmentation. In the long run, demand for the medical and health industry will constantly expand accompanied by population aging and consumption upgrading. This industry will represent a rising proportion in GDP.

Cherishing every investment and trust of our fund investors, the fund will always stand by the ChinaAMC principle of "Our Performance Your Trust", through standardized operation, prudent investment, and diligent pursuit of long-term and stable return delivery for investors.

Risk & Rating


Rating	Geometric Mean	Morningstar Risk	Morningstar Rating
3 Years	--	--	Not Rating
5 Years	--	--	Not Rating

MPT(3 Year)

Mean Return	--
Standard Deviation	--
Sharpe Ratio	--
Alpha	--
Beta	--
R-squared	--


Note: Benchmark is CSI Health Care PR CNY X 65% + SSE Government Yd CNY X 35%

Performance History 2016-07-31




Trailing Return	Total Return(%)	+/- Idx(%)	+/- Cat(%)
YTD	-6.39%	7.20%	7.24%
6 Months	22.12%	12.56%	7.66%
1 Year	0.67%	20.06%	4.62%
2 Years(annualised)	--	--	--
3 Years(annualised)	--	--	--
5 Years(annualised)	--	--	--
Since Inception	34.70%	--	--

Asset Allocation 2016-06-30



Asset Allocation: Asset allocation of Morningstar is calculated on the basis of net assets. "Others" equals to the difference between net asset and stock, bond & cash, reflecting the difference between asset items (excluding equities, fixed incomes, bank deposits and settlement provisions) and liabilities. "Others" in negative indicates that the fund has employed certain leveraged financing.

Morningstar Style Box 2015-12-31



Style Box

Style: Growth
Size: Large

Summary of Portfolio Holdings 2016-06-30

Top 10 Holdings - Equity	NetAsset
Zhenxing Biopharmaceutical and Chemical Co Ltd	9.11%
Guizhou Yibai Pharmaceutical Co Ltd	8.89%
Hybio Pharmaceutical Co Ltd	6.62%
Hualan Biological Engineering Inc	6.32%
Lepu Medical Technology (Beijing) Co Ltd	6.01%
Guangdong Kangmei Pharmaceutical Co Ltd	5.97%
Jiangsu Hengrui Medicine Co Ltd	5.21%
Beijing Tiantan Biological Products Corp Ltd	5.05%
Shanghai Pharmaceuticals Holding Co Ltd	4.20%
Shandong Shanda Wit Science And Technology Co Ltd	4.15%

Top 5 Holdings - Bond	NetAsset
-----------------------	----------

GICS Sector 2016-06-30

Sector Name	Equity NetAsset	NetAsset
Consumer Discretionary	5.43%	4.66%
Consumer Staples	0.12%	0.10%
Financials	0.17%	0.15%
Health Care	92.92%	79.75%
Industrials	0.24%	0.20%
Information Technology	0.87%	0.74%
Materials	0.17%	0.15%
Utilities	0.03%	0.03%
Others	0.06%	0.05%

NAV (2016-07-29):	1.3470(Yuan)
Accumulated NAV (2016-07-29):	1.3470(Yuan)
Total Net Asset (2016-06-30):	2.88(Billion Yuan)
Inception Date:	2015-02-02
Base Currency:	Yuan Renminbi
Manager:	CHEN Bin
Fund Company:	China Asset Mgmt Co.,Ltd
Hotline:	+86 10 88066688
Website:	www.chinaamc.com

The Highest Sales Fee

Subscription Fee	1.20%
Redemption Fee	1.50%

Initial Investment

Initial Investment	1,000(Yuan)
Additional Investment	--(Yuan)

Operation Fee

Management Fee	1.50%
Custodian Fee	0.25%
Distribution Fee	0.00%